Small caps or penny stocks have a psychological side to them. With a tremendous opportunity out there, it can be even said that small cap trading is a mindset. These companies have a reason to exist and one that is very important one to mankind. This reason is what makes everything different. Dyadic International Inc (NASDAQ: DYAI), Diginex (NASDAQ: IQOS) and Avicanna (OTC: AVCNF) are companies with a strong ‘why’ with which they are disrupting the world we know and possibly changing it for the better.
-
-
Dyadic is reinventing vaccines
-
Dyadic’s journey can be described as ‘from jeans to genes’ as it has been pioneering the use of pumice stones to stonewash blue jeans in the early 1980s, shifting along with the industry to enzymes in the middle of the decade, then beginning a new journey with the discovery of a filamentous fungal strain, nicknamed C1, suitable for producing cellulase and other enzymes in the early 1990s. Over the next two decades, Dyadic has built the knowledge, expertise, molecular tools, and technology needed to create and commercialize one of the world’s premiere gene expression systems that can respond to the pandemic of today and prepare for the pandemic of future, lowering prescription drugs tomorrow.
With a market cap of $169.6 million without debt, working to mass produce proteins that can be used in vaccines, therapeutic drugs as well as cancer and diabetes treatments, this company has immense potential to grow to a mid-cap and even a blue-chip. Their patented C1 technology comes with a next generation protein expression biotech that can bring biologic vaccines to market faster at lower cost. It is applicable to both the human and animal market so the addressable market is massive. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) might have gained this battle but this company can accelerate vaccine development and deliver a superior product that could even be safer as this is not the spike protein used in current mRNA vaccines. This technology will support and produce refined and better potency vaccine at higher volume and lower cost so the competitiveness of Dyadic’s excellence is undisputable.
-
Diginex created a transparent digital asset ecosystem
Traditional financial markets have so far escaped the disruption we have seen in other industries. Global lodging hospitality of 1.6 trillion has been disrupted by Airbnb (NASDSQ: ABNB) which just made its Wall Street Debut. Global passenger transportation worth $5.7 trillion has been shaken by Uber. Global online retail of $25 trillion has been defined by Amazon (NASDAQ: AMZN). And then, there are global capital markets equity and fixed income worth $178 trillion and Diginex which was launched just four months ago. Even PayPal (NASDAQ: PYPL) launched its cryptocurrency on October 21 st with DBS (OTC: DBSDY) and JP Morgan (NYSE: JPM) being the first banks to catch the crypto train.
But Diginex has created something more than an exchange. It created a full and pure play digital asset ecosystem that includes everything from crypto to securities and blockchain. Moreover, it is the first and only digital asset ecosystem comprising a crypto exchange to be listed on the NASDAQ. But most importantly, it is giving the transparency the world is asking for. This unique mid-cap is delivering on two opportunities. EQUOS offers the infrastructure necessary to meet the massive opportunity of crypto derivatives in a regulatory focused manner. EQUOS Capital covers digital securities, disruption of traditional financial markets through digital asset securization. Diginex created a regulatory-focused , institutional quality exchange, built to meet the derivative opportunity while offering the much needed protection against illegitimate projects.
-
Avicanna is bringing an advanced medical approach to cannabis
With legalization sweeping across the US with 36 countries legalizing cannabis for medical use and 15 states allowing recreational marijuana, it is important to make a distinction between the two approaches. Avicanna is a Canadian-based vertically integrated biotech biopharmaceutical company that specializes in medical cannabis. With an established and proven low-cost vertical integration that is both organic and sustainable, its R&D began inside Johnson & Johnson’s (NYSE: JNJ) innovation center JLABS.
Despite being Toronto-based, it is present in the US, Europe, LATAM and planning to launch in the UK next year. It operates in three segments, namely cosmetics, medical cannabis and pharmaceutical drugs, while owning all intellectual property that is utilizing. Its important to note that its hemp-derived cosmetics line is the only known CBD brand with human application trial data. Clinical trials for acne, anti-aging and many other skincare conditions have been completed and the results are being published. Its medical cannabis 2.0 products cover both CBD and THC and address secondary but major clinical symptoms such anxiety, depression, loss of appetite and sleep. It is one of the two companies that has the license to launch in Colombia as it’s important to note that while 91% of medical cannabis products out there are oil-based, Avicanna has a much more advanced formula. It also has pharmaceutical drugs in its portfolio that address a pipeline of rare diseases such as neuropathic pain of unknown origin and inflammation related to COVID-19.
With diversified, scalable and high margin revenue streams across several segments and geographic markets, this company is an intellectual market powerhouse.
The reason to be is key
Whoever reads the world news can see there is immense opportunity out there. The companies who succeed are the ones who know that we can always do better. It is about finding that motivation and doing your homework as trend is your friend. The above companies are doing an extraordinary job as they did their homework and analyzed what the world needs. Moreover, they took action and utilized their expertise to create solutions that satisfy urgent needs. Their reason for existence is their potential.
This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com